HRP20031028A2 - Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds - Google Patents

Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds Download PDF

Info

Publication number
HRP20031028A2
HRP20031028A2 HR20031028A HRP20031028A HRP20031028A2 HR P20031028 A2 HRP20031028 A2 HR P20031028A2 HR 20031028 A HR20031028 A HR 20031028A HR P20031028 A HRP20031028 A HR P20031028A HR P20031028 A2 HRP20031028 A2 HR P20031028A2
Authority
HR
Croatia
Prior art keywords
phenyl
heteroaryl
alkyl
naphthyl
hydrogen
Prior art date
Application number
HR20031028A
Other languages
English (en)
Croatian (hr)
Inventor
Brendel Joachim
Bhme Thomas
Peukert Stefan
Kleemann Heinz-Werner
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of HRP20031028A2 publication Critical patent/HRP20031028A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HR20031028A 2001-06-12 2002-05-31 Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds HRP20031028A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10128331A DE10128331A1 (de) 2001-06-12 2001-06-12 Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
PCT/EP2002/005956 WO2002100825A2 (de) 2001-06-12 2002-05-31 Anthranilsäureamide mit heteroarylsulfonyl-seitenkette und ihre verwendung als antiarrhythmische wirkstoffe

Publications (1)

Publication Number Publication Date
HRP20031028A2 true HRP20031028A2 (en) 2005-10-31

Family

ID=7687941

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20031028A HRP20031028A2 (en) 2001-06-12 2002-05-31 Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof as a medicament or diagnostic agent and pharmaceutical preparations containing said compounds

Country Status (40)

Country Link
US (2) US6903216B2 (enExample)
EP (1) EP1399423B9 (enExample)
JP (1) JP4422477B2 (enExample)
KR (1) KR100863924B1 (enExample)
CN (1) CN1247544C (enExample)
AR (1) AR036045A1 (enExample)
AT (1) ATE378318T1 (enExample)
AU (1) AU2002316939B2 (enExample)
BG (1) BG108415A (enExample)
BR (1) BR0210374A (enExample)
CA (1) CA2450076C (enExample)
CO (1) CO5540283A2 (enExample)
CR (1) CR7140A (enExample)
CY (1) CY1107427T1 (enExample)
CZ (1) CZ20033361A3 (enExample)
DE (2) DE10128331A1 (enExample)
DK (1) DK1399423T3 (enExample)
EC (1) ECSP034883A (enExample)
EE (1) EE05196B1 (enExample)
ES (1) ES2295360T3 (enExample)
HR (1) HRP20031028A2 (enExample)
HU (1) HUP0400159A3 (enExample)
IL (2) IL159247A0 (enExample)
MA (1) MA27037A1 (enExample)
MX (1) MXPA03010875A (enExample)
MY (1) MY138341A (enExample)
NO (1) NO20035450D0 (enExample)
NZ (1) NZ530081A (enExample)
OA (1) OA12631A (enExample)
PE (1) PE20021066A1 (enExample)
PL (1) PL364371A1 (enExample)
PT (1) PT1399423E (enExample)
RS (1) RS97703A (enExample)
RU (1) RU2293727C2 (enExample)
SK (1) SK15222003A3 (enExample)
TN (1) TNSN03134A1 (enExample)
TW (1) TWI304400B (enExample)
UA (1) UA75412C2 (enExample)
WO (1) WO2002100825A2 (enExample)
ZA (1) ZA200308520B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
HRP20041131A2 (en) * 2002-04-26 2005-08-31 Ishihara Sangyo Kaisha Ltd. Pyridine compounds or salts thereof and herbicides
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
DE10312061A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EP1489071A1 (en) * 2003-06-18 2004-12-22 4Sc Ag N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators
EP1651621B1 (en) 2003-08-08 2008-08-06 Janssen Pharmaceutica N.V. 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
US7297816B2 (en) 2004-09-24 2007-11-20 Janssen Pharmaceutica N.V. Sulfonamide compounds
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
CN101636154B (zh) * 2006-04-27 2011-12-14 塞诺菲-安万特德国有限公司 Task-1和task-3离子通道抑制剂
WO2008124524A2 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
EP2448909B1 (en) * 2009-06-29 2013-05-01 Merz Pharma GmbH & Co. KGaA Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
WO2011010132A1 (en) * 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
RU2414893C1 (ru) * 2009-11-11 2011-03-27 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Четвертичное аммониевое производное новокаина, обладающее противоаритмической активностью, и способ его получения
FR2967674B1 (fr) * 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (enExample) 2011-07-01 2018-04-28
JP2015504923A (ja) 2012-01-27 2015-02-16 ギリアード サイエンシーズ, インコーポレイテッド 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法
US9701627B2 (en) * 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
JP7205830B2 (ja) * 2017-08-07 2023-01-17 国立大学法人広島大学 新規アントラニル酸系化合物、並びにそれを用いたPin1阻害剤、炎症性疾患の治療剤及び癌の治療剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155662A1 (en) 1993-12-27 1995-07-06 Fumihiro Ozaki Anthranilic acid derivative
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
DK173062B1 (da) 1996-10-11 1999-12-13 Krueger As I Fremgangsmåde til fjernelse af opløste metaller og/eller metalloider fra et vandigt medium indeholdende samme og med et sto
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
CZ302691B6 (cs) 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
JP2002523451A (ja) * 1998-09-01 2002-07-30 ブリストル−マイヤーズ スクイブ カンパニー カリウムチャネル抑制剤および方法
WO2000078145A1 (en) * 1999-06-24 2000-12-28 Smithkline Beecham Corporation Macrophage scavenger receptor antagonists
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
CR7140A (es) 2004-04-15
HK1065316A1 (en) 2005-02-18
MA27037A1 (fr) 2004-12-20
RU2004100302A (ru) 2005-04-10
TWI304400B (en) 2008-12-21
UA75412C2 (en) 2006-04-17
PE20021066A1 (es) 2003-01-21
AU2002316939B2 (en) 2006-11-23
OA12631A (fr) 2006-06-14
RS97703A (sr) 2006-12-15
NO20035450D0 (no) 2003-12-08
AR036045A1 (es) 2004-08-04
ES2295360T3 (es) 2008-04-16
CO5540283A2 (es) 2005-07-29
IL159247A0 (en) 2004-06-01
BR0210374A (pt) 2004-07-13
CN1247544C (zh) 2006-03-29
HUP0400159A2 (hu) 2004-07-28
ZA200308520B (en) 2004-09-06
EP1399423B9 (de) 2008-02-27
CA2450076A1 (en) 2002-12-19
TNSN03134A1 (en) 2005-12-23
JP4422477B2 (ja) 2010-02-24
WO2002100825A3 (de) 2003-12-11
PL364371A1 (en) 2004-12-13
BG108415A (en) 2004-07-30
NZ530081A (en) 2005-07-29
US7235664B2 (en) 2007-06-26
KR100863924B1 (ko) 2008-10-17
EE05196B1 (et) 2009-08-17
DE10128331A1 (de) 2002-12-19
CN1529695A (zh) 2004-09-15
RU2293727C2 (ru) 2007-02-20
WO2002100825A2 (de) 2002-12-19
CY1107427T1 (el) 2012-12-19
EP1399423B1 (de) 2007-11-14
SK15222003A3 (sk) 2004-06-08
KR20040030668A (ko) 2004-04-09
CA2450076C (en) 2010-11-30
US6903216B2 (en) 2005-06-07
ECSP034883A (es) 2004-01-28
ATE378318T1 (de) 2007-11-15
DK1399423T3 (da) 2008-03-17
US20030114499A1 (en) 2003-06-19
CZ20033361A3 (cs) 2004-05-12
EP1399423A2 (de) 2004-03-24
IL159247A (en) 2010-06-16
MY138341A (en) 2009-05-29
MXPA03010875A (es) 2004-02-17
US20050137200A1 (en) 2005-06-23
EE200300558A (et) 2004-02-16
JP2004533464A (ja) 2004-11-04
PT1399423E (pt) 2008-02-07
HUP0400159A3 (en) 2008-10-28
DE50211213D1 (de) 2007-12-27

Similar Documents

Publication Publication Date Title
RU2293727C2 (ru) Амиды антраниловой кислоты с гетероарилсульфонильной боковой цепью и содержащие их фармацевтические композиции
RU2283833C2 (ru) Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции
KR101444489B1 (ko) 심혈관 질환을 예방 및 치료하기 위한 화합물
RU2275360C2 (ru) Ортозамещенные азотсодержащие бисарильные соединения для применения в качестве ингибиторов калиевого канала, а также содержащие их фармацевтические композиции
US8906946B2 (en) TRPM8 receptor antagonists
HRP20030436A2 (en) Ortho-substituted and meta-substituted bis-aryl compounds, method for the production thereof, theiruse as a medicament, and pharmaceutical preparations containing these compounds
JP2007525482A (ja) イオンチャネルリガンドとしてのアミド化合物およびその使用
MXPA06003951A (es) Derivados de amida como ligandos del canal de ion y composiciones farmaceuticas y sus metodos de uso.
JP4039625B2 (ja) アシルアミノアルキル置換ベンゼンスルホンアミド誘導体、それらの製造、それらの使用、および、それらを含む医薬製剤
JP2002520387A (ja) 2,5−置換されたベンゼンスルホニル尿素および−チオ尿素、それらの製法、それらの使用およびそれらを含有する医薬製剤
HK1064663B (en) Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof
CN120965608A (zh) 一种苯磺酰胺类化合物及其制备方法和应用
WO2021248256A1 (zh) 吡唑类化合物及其制备方法、用途和药物组合物

Legal Events

Date Code Title Description
A1OB Publication of a patent application
PNAN Change of the applicant name, address/residence

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, DE

ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20100529

Year of fee payment: 9

ODBC Application rejected